Table 1.

Summary of literature reporting response rates of HCC/CCC after SIRT

Author (year)	Patients n°	SIRT modality	Tumor response criteria	Tumor Response rate	Median OS (mo)
Cholangiocarcinoma
Soydal (2015) [11]	16	Resin	RECIST	PR: 30%	9.8
Filippi (2015) [12]	18	Resin	RECIST	PR: 82.3%	14.8
Camacho (2014) [13]	21	Resin	RECIST mRECIST EASL	PR: 4.7% PR: 62% PR: 9.5%	16.3
Rafi (2013) [14]	19	Resin	RECIST	PR: 11%	11.5
Mouli (2013) [15]	46	Glass	WHO	PR: 25%	14.6 (solitary) 5.7 (multifocal)
Hoffmann (2012) [16]	33	Resin	RECIST	PR: 36%	22
Haug (2011) [17]	26	Resin	RECIST	PR: 22%	11.7
Saxena (2010) [18]	25	Resin	RECIST	PR: 26%	9.3
Ibrahim (2008) [19]	24	Glass	WHO	PR: 27%	14.9
HCC
Mazzaferro (2013) [21]	52	Glass	EASL	CR: 9.6%; OR: 40.4%	15
Salem (2011) [22]	123	Glass	WHO/RECIST EASL	OR: 49% OR: 72%	20.5
Hilgard (2010) [22]	108	Glass	WHO/RECIST EASL	OR: 41% (CR 6%; PR 35%) OR: 40% (CR 3%; PR 37%)	16.4 10 (PVTT)
Salem (2010) [24]	291	Glass	EASL	OR: 57% (CR 23%; PR 34%)	17.2 (Child-Pugh A) 7.7 (Child-Pugh B)
Kooby (2010) [25]	27	Resin	WHO/RECIST	PR: 11%	6
Carr (2010) [26]	99	Glass	WHO/RECIST	OR: 41% (CR 3%; PR 38%)	11.5
Lewandowski (2009) [27]	43	Glass	WHO/RECIST EASL	PR: 61% (CR 0%) OR: 86% (CR 47%; PR 39%)	35.7
Kulik (2008) [28]	108	Glass	WHO/RECIST EASL	PR: 42% RR: 70%	NR
Sangro (2006) [29]	24	Resin	WHO/RECIST	DC: 100% RR: 23.8%	7
Salem (2005) [30]	43	Glass	WHO/RECIST EASL	PR: 47% PR: 79%	24 (Okuda I) 13 (Okuda II)
Carr (2004) [31]	65	Glass	WHO/RECIST	PR: 38.4%	21 (Okuda I) 10 (Okuda II)

OS=overall survival; OR (PR+CR)=objective response; DC=disease control; RR=reduction rate; WHO=World Health Organization; mRECIST=modified RECIST; EASL=European Association for the Study of the Liver; PVTT=portal vein tumor thrombosis.